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Background: The pre-surgical selection of thyroid nodules with indeterminate cytology (Thy 3 according to British
Thyroid Association) after fine-needle aspiration biopsy (FNAB) is currently required in order to reduce unnecessary total
thyroidectomy. The objective of our study was to use a surgical series of Thy 3 nodules to evaluate the predictive
role of ultrasound elastosonography (USE) and contrast-enhanced ultrasonography (CEUS) in pre-surgical diagnoses
of malignancy.
Subjects and methods: We enrolled 63 patients with Thy 3 nodules in which cytological–histological correlation was
available. The ELX 2/1 strain index was obtained by means of semi-quantitative USE, which was performed before
surgery in addition to conventional ultrasonography (US) and contrast-enhanced US (CEUS) on the Thy 3 nodules.
The ELX 2/1 strain index, a five-item US score and both peak (P) index and time to peak (TTP) index from CEUS were
correlated with the histological results. After surgical diagnosis, the data were analysed by using a receiver-operating
characteristic (ROC) curve.
Results: Histology was benign in 50 and malignant in 13 Thy 3 nodules. No difference in maximal diameter was noted
between benign (22.8 ± 1.6 mm) and malignant (18.9 ± 2.9 mm) nodules. Significant correlations were found between
histology and cumulative US findings (p=0.005), ELX 2/1 index (p=0.002), P index (p=0.01) and TTP index (p=0.02). On
analysing data from US, USE and CEUS, significant ROC areas under the curve were observed (p<0.0001). A cut-off
value was set for US (>2), ELX 2/1 (>0.95), P index (<0.99) and TTP index (>0.98) scores. The diagnostic power of the
cumulative pre-surgical analysis of Thy 3 nodules with US, USE and CEUS, considering the experimental cut-off points
obtained from the ROC curves was: sensitivity 64%, specificity 92%, PPV 75% and accuracy 84%.
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Conclusion: The ELX 2/1 index in conjunction with the US score can be useful in orienting surgical strategies in Thy 3
nodules. The information added by CEUS is less sensitive than that provided by US and USE. The use of a cut-off based
on histology can reduce thyroidectomy. Observation should be the first choice when not all instrumental results are
suspect.
Keywords: Thyroid nodules, Indeterminate cytology, Ultrasosonography, Ultrasound elastosonography, Strain index,
Contrast-enhanced ultrasonography, Cytological–histological correlation, ROC analysisIntroduction
The prevalence of diagnoses of thyroid nodules often
varies according to the method of examination used
[1-3]. The current thyroid nodule and thyroid cancer
epidemic can be explained by the worldwide diffusion of
ultrasonography (US) equipment [4,5]. When a nodule is
found, the most important clinical problem is to exclude
malignancy, which accounts for approximately 5%-15%
of all thyroid nodules [6-8]. A combination of clinical
factors (age, sex, exposure to radiation, familial traits)
and US features determines whether or not the clinician
should proceed with further tests or observation. The
accuracy of US in predicting thyroid cancer has recently
been reviewed by Brito et al. [9]. Only two US findings –
spongiform and cystic thyroid nodule features – seem to
provide sufficient probability to help rule out cancer and
to suggest observation at first, while all other US findings,
when assessed individually, might not be able to rule in or
rule out malignancy, owing to their modest likelihood
ratio [9]. Therefore, in order to distinguish malignant
from benign thyroid nodules, cytological investigation
by means of fine-needle aspiration biopsy (FNAB)
must be performed under US guidance in nodules larger
than 10 mm or with suspicious US findings [10-13].
Thyroid cytology is usually reported both descriptively and
as suggested categories with different risks of malignancy.
Both the Bethesda system and the British Thyroid
Association (BTA) category (Thy 1 – Thy 5) are used. The
ultimate aim of FNAB is to reassure the patient and to
avoid surgery if not otherwise indicated [13]. FNAB yields
useful cytological results in about 80% of cases, but has
several weaknesses, including false negative (about 1-2%),
non-diagnostic (3-16%) and indeterminate (follicular
lesions; 6-20%) results [13-16]. The low risk of underesti-
mating a thyroid cancer supports the recommendation for
repeat thyroid nodule evaluation 2–4 years after initial
benign (Thy 2) FNAB [16], while the very high probability
(77-100%) [17-21] of cancer in nodules “suspicious for
malignancy” (Thy 4) obliges surgery, as in the case of
findings that are “diagnostic of malignancy” (Thy 5).
Core-needle biopsy seems more useful than FNAB
repetition in reducing non-diagnostic (Thy 1) cytology
[22], but its utility in cases of indeterminate cytology
after FNAB is still debated [22,23]. As indeterminatelesions (Thy 3) are associated with an approximately
25% risk of malignancy [12,17,19,24-27], histological
examination is still required by the current guidelines
of thyroid societies. Rago et al. [27] recently reported an
overall good prognosis in Thy 3 lesions with malignant
histology, which suggests the possibility that more exhaust-
ive pre-surgical evaluation might reduce unnecessary
(about 70% of cases) surgery. In this context, the role of US
in distinguishing malignant from benign Thy 3 nodules is
still uncertain, though in the large series of Thy 3 nodules
examined in Rago’s study, blurred nodule margins and
spots of microcalcification were significantly associated with
malignancy.
The introduction of novel diagnostic tools may provide a
more reliable approach to assessing the risk of malignancy
in Thy 3 nodules. Recently, the determination of somatic
mutation in FNAB specimens from Thy 3 nodules has been
proposed [17,28,29], and may also help in deciding the
extent of surgery [30]. However, the role of molecular
screening could be overestimated, as this technique
increases FNAB sensitivity from 67% to only 75% in
indeterminate lesions [31]. On the other hand, a search
for several gene expressions conducted in 326 nodules
with indeterminate cytology has demonstrated the
substantial impact of this approach on clinical care recom-
mendations, though site-to-site variation exists [32] and
this evaluation is not yet universally available.
US elastography (USE) and contrast-enhanced US (CEUS)
are another two innovative techniques under evaluation for
the detection of malignancy in thyroid nodules, but
they still need validation. USE has been likened to
“electronic palpation” and provides reproducible stiffness
measurements even in otherwise non-palpable thyroid
lesions [33]. At present, heterogeneity among different
USE technologies (difference in compression source,
modality of processing, stiffness expression), equipment
and applications explains why USE is not yet part of
routine nodule management [19,33]. USE should primary
be implemented in the pre-surgical differential diagnosis
between benign and malignant nodules; however, its
accuracy is debated and surgery has not always been
taken as the reference in evaluating USE data [17-21,25].
In addition, a certain risk of false negative results has
been reported, especially in cases of follicular [34,35] or
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ation which enables thyroid nodules to be characterized
by studying vascular enhancement patterns, which it does
better than conventional US. Some authors have reported
that the absence of ring enhancement and the presence
of heterogeneous enhancement [37-39] or a shorter time
to peak of the perfusion curve [40] could characterize
malignant nodules. However, these data are still con-
troversial [19,41].
The pre-surgical diagnostic role of USE [17-19,21,25,42,43]
and CEUS [19,37] in nodules with indeterminate cytology
has been considered uncertain because of the low number of
these nodules in the series analyzed. Two recently published
studies have focused on USE in indeterminate nodules. In
169 patients in whom histology was available after qualitative
USE, Rago et al. [27] reported that high elasticity is closely
associated with benign histology, with a negative predictive
value of 97%. In addition, in a series of 270 nodules with
atypia of indeterminate significance evaluated by means of
semi-quantitative USE, Cakir et al. [44] reported a higher
median strain index in the malignant group than in the
benign group. To our knowledge, no data are available in
the literature on large series of Thy 3 nodules evaluated
by CEUS in order to judge the pre-surgical role of this
technique.
The aim of the present study was to retrospectively
evaluate the pre-surgical role of both USE and CEUS
together with US findings in our series of patients with
indeterminate cytology and known histology. The con-
struction of a validate cut-off for numerical indices could
be used to avoid surgical procedures in Thy 3 patients in
whom all tests (US, USE, CEUS) yield “benign” results.
The cost and time consumption of these techniques could
be lower than those of unnecessary thyroid surgery.
Materials and methods
Patients
This prospective study enrolled 78 consecutive patients
(60 female, 18 male; age: 20–82 yrs; mean ± SD: 55.4 ±
14.7 yrs) with thyroid nodules observed at the out-patient
Thyroid Cancer Unit. On FNAB, performed as previously
reported [19], all patients had an indeterminate thyroid
lesion (Thy 3) according to the 2009 BTA classification.
These patients were considered candidates for surgery in
accordance with the cytological result. In 47% of these
patients, the Thy 3 nodule was found in a multinodular
goitre, while 53% had a uninodular goiter. In 8 patients,
laboratory data were compatible with Hashimoto’s
thyroiditis, while one patient had a single Thy 3 nodule in
a diffuse toxic goiter. Levothyroxine was being taken by
20% of patients, either for hypothyroidism (n=3) or as a
TSH-reducing therapy (n=13). Three patients were on
methimazole therapy for pre-toxic goiter. All patients
underwent laboratory evaluations. TSH and free-T4 (f-T4)were measured by means of ultra-sensitive chemilumines-
cence immunoassay (Roche Diagnostics, Mannheim,
Germany). Normal ranges are: 0.3-4.2 mIU/l for TSH and
12.0-22.0 pmol/l for f-T4. Thyroperoxidase antibodies
(TPOAb) were evaluated by means of the Dia Sorin assay
(Saluggia, Italy); concentrations <100 mIU/l were regarded
as negative. Serum calcitonin (CT) was assayed by chemilu-
minescence immunoassay (Dia Sorin); in our laboratory,
the upper limit of the normal CT range is 10 ng/l.
All patients were invited to undergo further sonographic
evaluation. All patients gave their informed consent to
participate in the study. The collection of patient’s data
and subsequent analysis was performed in compliance
with the Helsinki declaration and was approved by
University of Genoa Ethical Committee.
Thyroid US, USE and CEUS
All patients were examined in the supine position
with the neck extended. Scans of both thyroid lobes
and isthmus were obtained in both transverse and
longitudinal planes. The Thy 3 nodules were examined by
means of conventional high-resolution US with a colour-
Doppler module (MyLab40, Esaote Biomedica, Genoa)
equipped with a 7.5 MHz linear probe. In 23 subjects, a
further FNAB was performed with the aid of this
equipment. As previously reported [19] and in accordance
with US guidelines [45], the following parameters were
investigated: echogenicity vs. non-nodular tissue, pres-
ence or absence of halo sign, presence or absence of
microcalcifications, and flow pattern of the nodule. All
USE examinations were performed by the same operator
(GT) by means of a MyLab 70 XvG US scanner (Esaote
Biomedica) equipped with an LA-522 linear probe
working in the range of 7–12 MHz and software for
the quantification of the USE features of the tissue.
Static and moving images were recorded, as already
reported by Lyshchik et al. [34], at least 3 times in
order to obtain mean values. The elasticity score
(ELX 2/1) index was calculated at the same depth as
the ratio between the elasticity feature of the selected
region-of-interest (ROI) located on US-normal thyroid
tissue and the ROI of the nodule under investigation. As
previously reported [19], we considered the ELX 2/1 index
directly reported on the screen of the equipment, as this is
a less operator-dependent variable than the elasticity
colour-scale extrapolated from breast tissue to the thyroid
gland by some authors [18,25,35,46]. CEUS images were
acquired by the MyLab 70 US scanner, as previously
reported [19], by using a non-destructive US mode after
bolus injection of SonoVue (4.8 ml; Bracco, Milan). CEUS
video-clips were digitally recorded and analysed by means
of Q-Contrast software V.4.0. (Bracco). Time-intensity
curves within selected ROI and colour maps were
acquired. Nodule and healthy thyroid tissue values of peak
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were calculated. Peak and TTP are reported as indexes
(Peak index, TTP index) derived from the ratio between
the values from the ROI of the nodule and the ROI
of normal thyroid tissue [19].
Statistical analysis
Non-parametric tests were used to compare averages;
the correlation coefficient r was calculated by means of
Spearman correlation (Sr) (GraphPad 6.0 Software, San
Diego, CA, USA). Data are reported as mean ± standard
error of mean (SEM) if not otherwise reported. Significance
was set at p ≤ 0.05. A US score (from 0 to 5) was arbitrarily
calculated for the nodule under evaluation, with one point
being assigned for the presence of each of the following
radiological findings: solid, hypo-echoic, microcalcification,
internal vascularisation, and irregular shape [19]. All
cytological and histology diagnoses were made by a
pathologist (BM) with 10 years’ experience in the pathologic
analysis of thyroid cancer. After surgery, Thy 3 lesions were
classified as malignant or benign. The diagnostic value of
the ELX 2/1 index from USE or the P index and TTP
index from CEUS in distinguishing between benign
and malignant nodules was analysed by means of the
receiver-operating characteristic (ROC) curve and calculated
area under the curve. After using this curve to establish a
cut-off point, we established sensitivity and specificity values
and likelihood ratios. The cumulative results from US, USE
and CEUS were evaluated for sensitivity, specificity, positive
predictive value and accuracy. Thy 3 nodules that fitted all
experimental cut-off points obtained from ROC curves were
considered true positive if they proved malignant and falseTable 1 Clinical and instrumental data on Thy 3 nodules with
# Age (yrs) Sex Nodule size (mm) US (score) USE (ELX 2/
1 23 m 25 3 1.10
2 34 m 9 3 1.90
3 36 f 20 3 1.53
4 40 f 15 1 1.50
5 45 f 30 4 3.00
6 45 f 44 4 ne
7 46 f 7 4 1.00
8 46 f 9 3 1.30
9 50 m 13 3 1.80
10 54 m 20 3 1.70
11 66 m 23 5 1.50
12 71 f 7 3 1.90
13 74 f 22 3 2.00
(°) FTC = follicular thyroid carcinoma; MTC = medullary thyroid carcinoma; FvPTC =
thyroid carcinoma.
(*) Tumour stage on diagnosis according to AJCC/UICC 2010 Seventh Edition criteri
ne = not evaluable owing to coarse calcification (case #6).positive if they proved benign on histological examination.
In addition Thy 3 nodules that did not fit all experimental
cut-off points obtained from ROC curves were considered
true negative if they proved benign and false negative if they
proved malignant on histology.
Results
At the time of FNAB evaluations, all patients had normal
f-T4 (15.1 ± 0.3 pmol/l) and TSH (2.0 ± 0.2 mIU/l) levels.
CT was in the normal range in all but two patients; in
these two patients, CT levels above the upper limit of the
normal range (20 ng/l and 27 ng/l) were recorded. Surgery
was performed in 63 of the 78 patients (81%). Surgery was
not performed in 19% of Thy 3 nodules for the following
reasons: down-grading of BTA classification from Thy 3
to Thy 2 (benign lesion) after the second FNAB (n=6),
patient lost (n=4), patient request for further follow-up
(n=2), patient refusal (n=2) and severe comorbidity (n=1).
After surgery, a benign histological diagnosis of the
cytological Thy 3 nodule was found in 50 cases (25
hyperplastic nodules; 18 follicular adenomas; 6 Hürthle
cell adenomas; 1 intra-thyroid parathyroid adenoma). In 9
of these 50 cases (18%) an extra-nodular focal lymphocytic
thyroiditis pattern was found, and in 6 (12%) a
micro-papillary carcinoma of the isthmus (n=1) or in
the contralateral lobe (n=5) was incidentally found. In
one patient, C-cell hyperplasia was described. A final
diagnosis of malignancy in the cytological Thy 3 nodules
was reported in 13 cases (21%) (5 papillary thyroid carcin-
omas; 5 follicular variants of papillary thyroid carcinomas;
2 follicular carcinomas; 1 medullary thyroid carcinoma).
Table 1 reports the clinical details of patients with thyroidproven malignancy on histology
1) CEUS P index TTP index Histology (°) Tumour stage (*)
0.75 0.90 FTC 1
0.86 1.10 MTC 1
0.69 1.07 FvPTC 1
1.00 1.00 FTC 1
0.69 1.25 FvPTC 3
0.82 1.62 FvPTC 3
0.60 0.63 PTC 1
0.95 1.20 FvPTC 1
0.33 1.00 PTC 3
0.90 2.40 PTC 1
0.80 1.01 PTC 1
0.77 1.00 PTC 1
0.90 1.00 PTC 1
follicular variant of papillary thyroid carcinoma; PTC = papillary
a.
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between Thy 3 nodules with benign (22.8 ± 1.6 mm) or
malignant (18.9 ± 2.9 mm) histology.
A significant correlation was seen between cumulative
US findings and histology (n=63, Sr 0.35; p=0.005). A
ROC curve was obtained (Figure 1) with an area under
the curve (AUC) of 0.97 ± 0.01 (p<0.0001). By establishing
a cut-off level that classified Thy 3 nodules with a US
score greater than 2 as malignant, we were able to achieve
a sensitivity of 79.0% and a specificity of 100%, with a 5.0
likelihood ratio.
USE was available in 61 Thy 3 nodules before surgery. In
the remaining 2 cases, the ELX 2/1 index was unobtainable
owing to coarse calcification of a 44 mm malignant nodule
and the loss of data in a 23 mm benign nodule. A significant
correlation was seen between the ELX 2/1 index and
histology (Sr 0.39; p=0.002). A ROC curve was obtained
(Figure 2) with an AUC of 0.95 ± 0.02 (p<0.0001). By
establishing a cut-off level that classified Thy 3 nodules
with an ELX 2/1 index greater than 0.95 as malignant, we
were able to achieve a sensitivity of 83.6% and a specificity
of 80.3%, with a 4.2 likelihood ratio. No significant correl-
ation was found between the ELX 2/1 index and nodule
(maximal) size or cumulative US findings (score).
CEUS was performed on 53 Thy 3 nodules; no side
effects were recorded during or immediately after injection
of the contrast agent. CEUS could not be performed in 10
Thy 3 nodules owing to refusal of intravenous injection of
the contrast agent (n=5), technical impossibility of
recording adequate video-clips (n=3) and loss of data
(n=2). All these Thy 3 nodules (size-range: 14–30 mm)Figure 1 ROC curve created with histology as a reference for
distinguishing malignant from benign Thy 3 nodules according
to US score. The best cut-off was >2.had benign histology. A significant inverse correlation was
observed between histology and P index (Sr −0.37; p=0.01)
while a significant positive correlation was found between
histology and TTP index (Sr 0.32; p=0.02). ROC curves
were obtained for the P index and TTP index, with an
AUC of 0.83 ± 0.04 (p<0.0001) and 0.86 ± 0.04 (p<0.0001),
respectively (Figure 3). By establishing a cut-off level that
classified Thy 3 nodules with a P index lower than 0.99 as
malignant, we were able to achieve a sensitivity of 37.7%
and a specificity of 75.5%, with a 1.5 likelihood ratio. By
establishing a cut-off level that classified Thy 3 nodules
with a TTP index greater than 0.98 as malignant, we were
able to achieve a sensitivity of 56.6% and a specificity of
75.5%, with a 2.3 likelihood ratio. A significant inverse
correlation was found between P index and US findings
(score) (Sr −0.44; p=0.001). The peak index was not
related to nodule size, while the TTP index was not
related to either US findings (score) or nodule size.
A cohort of 51 Thy 3 cases underwent US-guided
FNAB, USE and CEUS before surgery. In 9 out of 12 (75%)
histologically malignant Thy 3 nodules, all indictors were
positive for malignancy, while they were all positive in 5
out of 39 (13%) histologically benign Thy 3 nodules. The
diagnostic power of the cumulative pre-surgical analysis
of Thy 3 nodules by means of US, USE and CEUS,
considering the experimental cut-off points obtained
from ROC curves was: sensitivity 64%, specificity 92%,
PPV 75%, and accuracy 84%.
Discussion
The number of thyroid cancer diagnoses is currently
increasing. This is probably the result of a reservoirFigure 2 ROC curve created with histology as a reference for
distinguishing malignant from benign Thy 3 nodules according
to USE ELX 2/1 strain index. The best cut-off was >0.95.
Figure 3 ROC curve created with histology as a reference for
distinguishing malignant from benign Thy 3 nodules according to
CEUS. The upper panel reports the P index; the best cut-off was <0.99.
The lower panel reports the TTP index; the best cut-off was >0.98.
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roid disease which is disclosed in parallel with the
“epidemic” of thyroid nodules due to the increase in
instrumental, mainly US, diagnostics. Current clinical
efforts should be aimed at defining the nature (malignant
or benign) of a given nodule and identifying the relatively
rare malignant nodules, in order to reduce unnecessary
invasive surgical procedures.
US, which is the most sensitive means of evaluating
thyroid morphology, can evaluate the size and characteris-
tics of non-palpable nodules, reveal lymph-node metastases
and guide FNAB. It is well known that no single US pattern
can be used alone as a definite criterion of malignancy [45],and individual US features are not now considered accurate
predictors of thyroid cancer [9].
The present study demonstrates that, in Thy 3 nodules,
nodule size is not a useful means of distinguishing
malignant from benign nodules, as already reported
by several other authors [12,27,47]. In a previous study
involving five US parameters (hypoechogenic, solid,
intra-nodular vascularization, microcalcifications, and
irregular margins), we found that the diagnostic power of
color-Doppler US was high; indeed, 100% of nodules in
which four or five these parameters were positive proved
to be malignant [19]. Similarly, on using the so-called
“thyroid imaging reporting and data system”, Horvath et al.
[48] found malignancy in 80% of nodules classified as
probably malignant on US. A limitation of these studies,
however, was the 5-14% of false negative results in nodules
with a low number of suspicious US features [19,48]. In a
very large series of Thy 3 nodules, Rago et al. [27] recently
reported a significant association of three suspicious US
features (blurred margins, spot microcalcifications and
hypoechogeneicity) with malignancy. Moreover, in the
present study, a significant correlation was found between
cumulative US findings and histology, and the ROC curve
analysis indicated that the presence of more than two
suspicious US findings in Thy 3 nodules reached a
sensitivity of 82% and a specificity of 100%, with a
5.0 likelihood ratio. In a series of 40 Thy 3 nodules
with US available for review, Matthey-Gie et al. [49]
reported that high nodule vascularity associated with
ill-defined borders was a suspicious US finding linked
to malignancy. In a series of 78 indeterminate lesions,
Batawil and Alkordy [50] found that solid structure
and irregular border were the most suspicious findings.
Yoo et al. [26] examined a selected series of 249 nodules
which met the criteria of atypia or follicular lesion of inde-
terminate significance and in which core-biopsy or surgery
were used as references; they observed that taller-than-wide
shape and marked hypoechogenicity were highly suspicious
US findings. In 61 follicular neoplasms and 99 Hürthle cell
neoplasms, Tutuncu et al. [51] did not report the role of
cumulative US findings; however, they indicated that
hypoechogenicity and microcalcification had the highest
odds ratios. In sum, in Thy 3 nodules, US is helpful to the
initial decision-making process, but combination with other
evaluations is needed.
More recently, USE machines able to measure tissue
hardness qualitatively (colour score), semi- quantitatively
(strain ratio), or quantitatively (elasticity index, shear-wave
velocity) have been introduced into the clinical setting in
order to overcome the limitations of FNAB and US in
thyroid nodules [33]. The efficacy of USE in distinguishing
benign from malignant thyroid nodules varies widely among
studies [17-20,25,34,35,46,47,52]). In a 2013 meta-analysis
by Razavi et al. [53], in which 24 studies comprising 3531
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those yielded by US, USE was reported to be more sensitive
(colour score 82%; strain ratio 89%) and specific (colour
score and strain ratio 82%) than each individual US feature.
However, in a previous study in which we evaluated a subset
of 27 Thy 3 nodules with cytological-histological correlation
by means of semi-quantitative USE, we were unable to
distinguish these nodules from cytological benign (Thy 2) or
malignant (Thy 5) nodules on the basis of the ELX 2/1
strain index [19]. The only reported finding was an
increasing trend in low-range ELX 2/1 strain index values
from Thy 2 to Thy 5 nodules [19]. In the present study,
which involved a higher number of Thy 3 nodules, the
ELX 2/1 strain index showed a significant correlation with
histology, and the established cut-off level, which classified
Thy 3 nodules with an ELX 2/1 index greater than 0.95
as malignant, showed better sensitivity of 83.6% and
specificity of 80.3%, with a 4.2 likelihood ratio. In the
study by Rago et al. [27], qualitative USE was performed
in 169 Thy 3 nodules in which cytological-histological
correlation was available, and low stiffness was found in
nodules with benign diagnoses, the negative predictive
value of 97% increasing the predictivity of US features. In
several other studies on the pre-surgical utility of USE in
thyroid nodules, the number of indeterminate lesions was
limited, ranging from 9 to 58 [17,21,43,47,53], and
separate data analysis was either not done [17] or,
when done, was poorly understandable [21] or revealed
low sensitivity (78%) and specificity (44%) [47]. Similarly, a
very low specificity (6%) was observed in a study by
Lippolis et al. [46], which evaluated 103 nodules with
indeterminate cytology. On the other hand, in 270
nodules cytologically classified as atypia of undetermined
significance by means of qualitative and semi-quantitative
USE, Cakir et al. [44] reported favourable conclusions,
suggesting the use of this technique in the pre-surgical
evaluation of indeterminate nodules. The best strain index
value in distinguishing between cytologically benign and
cytologically malignant nodules reaches a sensitivity of
99% and a specificity of 96%.
Overall, the diagnostic utility of USE in Thy 3 nodules
remains under evaluation. However, qualitative and semi-
quantitative methods and definite cut-off values obtained
in large numbers of subjects have yielded promising
results (present study, [27,44]), thus supporting a less
aggressive strategy, especially when no suspicious features
are noted on US.
The latest technique involving US for the study of
thyroid vascularization uses a microbubble contrast
agent. It is well known that the thyroid gland has an
abundant microvasculature, and that the parenchyma of
normal thyroid shows rapid and uniform enhancement
after intravenous injection of contrast agents. By contrast,
the vascular structure of nodules differs from the normalpattern, and hence enhancement differs from that of the
normal parenchyma. Argalia et al. [54] have shown that
CEUS time-intensity curves can provide an indirect
description of intra-nodular vascularization, which seems
to be anarchic in malignant nodules. Literature data on
the utility of CEUS in distinguishing malignant from
benign nodules are controversial. Zhang et al. [37]
reported that heterogeneous enhancement rendered a
thyroid nodule suspicious for malignancy, while
Friedrich-Rust et al. [41] reported that the time-intensity
CEUS curve did not prove useful in distinguishing between
benign and malignant nodules. Moreover, in our previous
report [19], the P index and TTP index were found to be
unrelated to cytological and histological results. More
recently, two studies involving Chinese patients examined
the role of CEUS in distinguishing between malignant and
benign thyroid nodules. In 175 nodules, without histo-
logical reference in all cases, Deng J et al. [39] reported a
CEUS sensitivity of 82% and a specificity of 85%. Their
study was based on the impression that hypo-enhancement
could be regarded as an indicator of malignancy. Ma et al.
[38] studied the preoperative diagnostic role of CEUS
combined with US in 172 nodules, all surgically removed.
Both US and CEUS areas under the ROC curves were
significant, but the best sensitivity (89%) and specificity
(94%) was reached by considering five positive features
(ring enhancement, homogeneity of enhancement, arrival
time of the nodule at CEUS, microcalcifications, and halo
sign on US) on combining US and CEUS.
To our knowledge, no studies on CEUS have focused
on the subpopulation of indeterminate nodules. In our
previous study on CEUS in thyroid nodules, CEUS was
available in 17 indeterminate nodules with cytological-
histological correlation [19]. Regarding the indicators
P index and TTP index, no differences were noted
among the nodules scored according to the Thy classifica-
tion [19]. The present study provided more interesting data.
Significant correlations were noted between histology and
both P index (negative) and TTP index (positive). The areas
under the ROC curves for the P index and TTP index were
significant at an established cut-off level that classified Thy
3 nodules as malignant when the P index was lower than
0.99 (sensitivity 37.7%; specificity 75.5%) and the TTP index
was greater than 0.98 (sensitivity 56.6%; specificity 75.5%).
Our experience of Thy 3 nodules seems to indicate a
greater diagnostic role of semi-quantitative USE than
of CEUS. In the study by Deng et al. [39], however,
quantitative USE and CEUS displayed the same value in
distinguishing between benign and malignant nodules.
The simultaneous evaluation of different indicators from
US, USE and CEUS and the use of validated cut-off levels
for interpreting data – without or with low subjectivity –
is crucial in clinical decision-making when cytological
results are indeterminate and lobectomy or thyroidectomy
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fully evaluable, our study indicates that the diagnostic
power of the cumulative pre-surgical analysis of Thy 3
nodules by means of US, USE and CEUS does not
increase sensitivity (64%) but improves specificity
(92%); moreover, it showed interesting levels of PPV
(75%) and accuracy (84%). While false negative (25%)
and false positive (13%) results are limitations, these
preliminary data on the combination of US, USE and
CEUS with FNAB seem to provide promising indications
that unnecessary lobectomy/thyroidectomy can be
reduced. To our knowledge there are no studies on
Thy 3 nodules in which results obtained from conventional
US, USE and CEUS have been simultaneously scored in
order to make a clinical decision. In our opinion,
US-guided FNAB remains the gold standard in solid
nodules. However, when an indeterminate response
emerges from cytology, surgery may be postponed if
no suspicious findings are observed (in our hands:
US score ≤ 2, ELX 2/1 <0.95, P index >0.99 and TTP
index <0.98).
There are some limitations to this study. First, the
number of fully evaluable Thy 3 nodules was small. As
the thyroid tissue adjacent to the Thy 3 nodule may not
be normal, both USE and CEUS may sometimes be
impracticable. Moreover, injection of the contrast agent
before CEUS is sometimes refused by the patient.
Second, we did not divide FNAB results into Thy 3
atypia and Thy 3 follicular neoplasm, as suggested by
the BTA in 2014 [27,43]. Larger numbers of Thy 3 nod-
ules could necessary in order to compare USE and
CEUS data in these two Thy 3 subpopulations. Third,
genetic markers were not considered in the present
study; however, BRAF, the most frequent mutation in
thyroid cancer, seems to be less important in follicular
neoplasms [31]. Fourth, this was a single-centre study.
However, pooling data from different centres for qualitative
and semi-quantitative USE remains impracticable, since
different devices may yield various types of strain indices,
such as maximum ratio or simple ratio. While we used an
average ELX 2/1 index from at least 3 measures, it is
unclear whether the average index is truly representative of
nodular stiffness. Among our Thy 3 lesions, medullary
carcinomas and follicular carcinomas were rare (25% of
Thy 3 nodules with histological malignancy). According to
some authors [34-36,39], however, false negative results
from these tumours should be taken into consideration
when USE and CEUS data are evaluated.
In conclusion, in cytologically Thy 3 nodules, conven-
tional US must be associated, when feasible, to the com-
bined application of USE and CEUS. The use of a cut-off
based on histology can reduce the surgical approach.
Observation should be the first choice when not all
instrumental results are suspect.Competing interests
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